Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of EGR2-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of EGR2-positive cells being characterized in that it also expresses ACTA2, ADORA3 and MYH11.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in mouse cortex of an exogenous gene in a particular population of CNR1-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of CNR1-positive cells being characterized in that it also expresses EFHD1, ENPP6 and GJC2.

Abstract: The present invention provides a method of screening for psychoactive agents comprising the steps of a) simultaneously assessing in a subject, the activity of neurons of at least two regions of the deep cortical layers in the absence of a potential psychoactive agent and correlating these activities, b) simultaneously assessing in said subject, the activity of said neurons of said at least two regions of the deep cortical layers in the presence of the potential psychoactive agent and correlating said activities, and c) comparing the correlations obtained in step a) and b), wherein any significant change in the correlation obtained in step b) as compared to the correlation obtained in step a) is indicative of a potential psychoactive activity of said potential psychoactive agent.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 500 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of DLX4-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, said particular population of DLX4-positive cells being characterized in that it also expresses VTN, ABCC9 and CLDN5.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1, or of a nucleic acid sequence of at least 700 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression in layer 2/3 of mouse cortex of an exogenous gene in a particular population of CUX1-positive cells when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule, particular population of CUX1-positive cells being characterized in that it also expresses FLT1, CSF3R and CLDN5.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or of a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule leads to the specific expression of an exogenous gene in agmat-positive cells in layer ? of mouse cortex when a nucleic acid sequence coding for said exogenous gene is operatively linked to said isolated nucleic acid molecule.

Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in cells expressing glial fibrillary acidic protein of a gene when operatively linked to a nucleic acid sequence coding for said gene.

Abstract: In a combustion chamber for a gas turbine, noise absorption is achieved over a wide frequency range with simultaneous cooling of the arrangement and low space requirement by the inner wall being formed, at least in a partial region of the inner walls by at least two perforated plates arranged essentially parallel to one another, and by the distances between the perforated plates and the geometrical dimensions of the openings being selected in such a way that a plurality of mutually connected Helmholtz resonators is formed and that, in addition, further expedients are available which act to absorb noise.